Reply To: SARS cov2 and Covid 19

[Clark]

Here is the paper on ADE:

An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies

– These findings suggest that the production of antibodies against SARS-CoV-2 infectivity-enhancing site could be considered as a possible exacerbating factors for COVID-19 and that a spike protein lacking such antibody epitopes may be required for safe vaccine development, especially for individuals with pre-existing enhancing antibodies.

Roland Baker, Molecular Genetics, U.C. Berkeley Alumnus:

– “Well I’m terrified now.”

Twitter @RolandBakerIII, 20 hours ago.